Neumora Therapeutics, Inc. - NMRA Book Capitalization

Official company branding of Neumora Therapeutics, Inc. (NMRA)

Neumora Therapeutics operates within a stable US legal framework, protected from sanctions by its humanitarian status. The firm's strategy is based on expanding its portfolio of precision CNS drugs through late-stage trials. The company's price chart on the GURU.Markets platform recorded a value of 0.04. Business development relies on regulatory approvals, biomarker efficacy, and a steady flow of investment into scientific research.

NMRA: Neumora Therapeutics, Inc. Book Capitalization 02/21/2024 - 10/29/2026

NMRA (Neumora Therapeutics, Inc.): analytical breakdowns and indicator data

- current price and projected stock value:
Price Performance Chart Neumora Corp|NMRA - Analyst Consensus Forecast
- issuer market value details:
Market Capitalization Neumora|NMRA - Total Company Value
- shareholders' equity book value data:
Equity per Share Neumora Therapeutics|NMRA - Book Capitalization|Market-to-Book Ratio neumoratx.com|NMRA - Cumulative Company Assets
- debt and liquidity data:
Total Debt to Capital Neumora Therapeutics|NMRA - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Neumora|NMRA - Company Debts|Debts to Book Value Neumora|NMRA - Company Long-Term Debt|Company Short-Term Indebtedness Neumora Therapeutics
Initial company analysis:NMRA, Neumora Corp
Mass-produced product of Neumora

Market expectations often diverge from the actual net asset value of biotech startups. The valuation of the company's book capitalization is based on a daily recalculation of asset values, neutralizing gaps between quarterly reports. This indicator measures the actual capital available for development. For Neumora Therapeutics (NMRA), it reflects the burn rate of resources allocated to clinical trials. The absence of commercial revenue makes this metric a key measure of business viability.

Competitor analysis

Accounting Value of Company BIIB (Biogen Idec)|NBIX: Book Capitalization|regencellbioscience.com (RGC) - Book Capitalization|Company Book Value Axsome Therapeutics, Inc.|Accounting Capitalization ACAD (ACADIA Pharma)|Book Capitalization XENE|VKTX - Total Stockholders' Equity|Supernus Pharmaceuticals - Company Net Assets|Book Capitalization catalystpharma.com CPRX|DNLI - Company Book Value|Accounting Value of Company HRMY (Harmony Biosciences Inc)|Biohaven Pharmaceutical (BHVN) - Company Book Value|Total Stockholders' Equity Amylyx Corp (AMLX)|Company Book Value Trevi Therapeutics|Accounting Capitalization PRAX (praxismedicines.com)|Book Capitalization AVXL|CBLL - Total Stockholders' Equity|prothena.com - Company Net Assets|Book Capitalization Alector Inc. ALEC|ANNX - Company Book Value|Omeros Corporation (OMER) - Company Net Assets|Neurogene (NGNE) - Company Book Value|Total Stockholders' Equity AC Immune S.A. (ACIU)|Company Book Value Voyager Pharma|SCLX: Accounting Value of Company|Book Capitalization TVGN|Book Capitalization alphacognition.com (ACOG)|Cognition Therapeutics - Company Net Assets|Accounting Value of Company IKT|SAVA: Company Net Assets|Assertio Holdings, Inc. - Total Net Assets|COYA: Book Capitalization|Vistagen - Accounting Value of Company|OVID (Ovid Therapeutics Inc) - Book Capitalization|Total Stockholders' Equity Acumen Pharmaceuticals Inc. ABOS|Company Book Value CervoMed Inc (CRVO)|ATHE (alteritytherapeutics.com) - Accounting Value of Company|Book Capitalization CLNN (Clene)|Book Capitalization PepGen Inc PEPG|JUNS - Company Book Value|Net Asset Value RLMD|ANVS: Book Capitalization|Total Stockholders' Equity Grace Therapeutics (GRCE)|Company Net Assets AIFF|Book Capitalization ANEW Medical, Inc.|Company Net Assets NRSN (NeuroSense Therapeutics)|Total Net Assets RVPH|Book Capitalization MTVA (MetaVia)|Book Valuation of Business NeurAxis Inc (NRXS)|Helius Medical Technologies Inc. - Book Capitalization|Passage Bio, Inc. (PASG) - Company Net Assets|bionomics.com.au (NEUP) - Company Book Value|NERV - Book Valuation of Business|Company Book Value Athira|Accounting Capitalization ADXN (Addex)|Company Book Value Alzamend Neuro, Inc. (ALZN)|Company Net Assets cyclerion.com CYCN|Company Book Value Protagenic Therapeutics, Inc. PTIX|Accounting Value of Company KTTA|Cortigent Medical - Book Capitalization|ATXI - Book Capitalization|Brainstorm Cell (BCLI) - Company Book Value|Accounting Capitalization CARA|CHRO (Chromocell Therapeutics Corp.) - Book Capitalization|Total Stockholders' Equity Eliem ELYM|Company Net Assets ITCI (Intra-Cellular Therapies)|Book Capitalization Longboard (LBPH)|Company Book Value Marinus Pharmaceuticals MRNS|Accounting Value of Company NKGN|NRBO - Company Book Value|Total Stockholders' Equity Sage Therapeutics Inc.|Neurotrope (SNPX) - Company Book Value|Accounting Capitalization TRVN|VIGL (Vigil Neuroscience Inc.) - Book Capitalization|Total Stockholders' Equity Anew Medical Inc. WENA|Company Net Assets CERE (Cerevel Therapeutics, Inc.)